Cure My Disease

Don't miss your cure!

 Log in / Sign up

Drug interaction study aims to uncover how ALXN2050 behaves with fluconazole and rifampin

NCT ID NCT04933682

Completed Knowledge-focused Sponsor: Alexion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This phase 1 study investigates whether the experimental drug ALXN2050 interacts with fluconazole (an antifungal) and rifampin (an antibiotic) in healthy adults. Researchers will measure how the body processes ALXN2050 when taken alone versus with each of these drugs. The goal is to understand potential changes in drug levels and safety, which will guide future dosing recommendations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ALXN2050, fluconazole, and rifampin
What this could lead to
If successful, this study will clarify how ALXN2050 interacts with common medications, helping doctors dose it safely in future patients.
What could go wrong
This is an early-phase study in only 16 healthy people, so results may not predict effects in patients or cover all drug combinations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

  • Clinical Trial Site

    Tempe, Arizona, 85283, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.